🔍

Shukra Pharmaceuticals Ltd (524632)

📊 BSE: 524632 🏢 Pharmaceuticals 📢 Latest filing: 12 Oct 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Shukra Pharmaceuticals' revenue was ₹23.5 Cr, and net profit ₹13.0 Cr; the operating margin was 81.4%.

Q1 FY27 (₹ Cr)	Value	YoY	QoQ
Revenue	₹23.5	—	+272.2%
Operating profit	₹19.1	—	—
Net profit	₹13.0	—	from loss
EPS (₹)	0.30	—	from loss
Operating margin	81.4%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Shukra Pharmaceuticals Receives MCA Approval for Name Change to Shukra Medtech Limited

🟡 NEUTRAL ⭐ 3/10

OTHER 📅 12 Oct 2026, 07:04 PM

Shukra Pharmaceuticals Limited has received approval from the Ministry of Corporate Affairs (MCA) to change its name to 'Shukra Medtech Limited'. Consequent to this, the Registrar of Companies issued a fresh Certificate of Incorporation dated October 12, 2026. The company stated the reason for the change is business restructuring and alignment with future corporate strategy and medical-technology operations. The company is now completing formalities with stock exchanges to update records and shift to a new trading symbol.

MCA and RoC approved the company name change on October 12, 2026
Old name: 'Shukra Pharmaceuticals Limited'; New name: 'Shukra Medtech Limited'
A fresh Certificate of Incorporation was granted by the Central Processing Centre on October 12, 2026
Company is initiating processes with BSE and NSE to adopt a new trading symbol

💡 Track the upcoming exchange notification regarding the effective date of the trading symbol change and observe whether management announces concrete capital allocation toward medical technology operations.

Shukra Pharma Allots 17.35 Lakh Shares on Warrant Conversion, Raises ₹4.63 Cr

🟡 NEUTRAL ⭐ 4/10

FUNDRAISE 📅 06 Oct 2026, 06:42 PM

Shukra Pharmaceuticals has approved the allotment of 17,35,000 equity shares of face value ₹1 each upon the conversion of warrants to promoter entities. The company received the remaining 75% exercise price of ₹26.67 per warrant, bringing in ₹4.63 crore in cash against an issue price of ₹35.56 per share. With this conversion, all 46,43,000 warrants allotted on January 28, 2026, stand fully converted with zero outstanding warrants remaining. Paid-up equity capital increased marginally to ₹44.25 crore from ₹44.08 crore.

Allotment of 17,35,000 equity shares of Re 1 face value to promoter entities upon warrant conversion
Received balance 75% consideration of ₹26.67 per warrant, aggregating to ₹4,62,72,450
Warrant issue price fixed at ₹35.56 each, representing a discount to the current market price of ₹54.6
Total outstanding warrants reduced to 0 from the original 46,43,000 allotted on January 28, 2026
Paid-up equity share capital increases from ₹44,07,87,440 to ₹44,25,22,440

💡 Track the listing and trading approval of the newly allotted shares on the stock exchanges and monitor subsequent quarterly shareholding patterns.

Shukra Pharma Approves Rebranding to 'Shukra Medtech' and Expands MOA into Medical Devices

🟡 NEUTRAL ⭐ 5/10

BOARD_MEETING 📅 22 Aug 2026, 02:50 PM

Shukra Pharmaceuticals Ltd's Board has approved changing the company's name to 'Shukra Medtech Limited', subject to regulatory and shareholder approvals. The company is altering its Memorandum of Association (MOA) to expand its main objects into medical devices, surgical robotics, AI-based healthcare technologies, and MedTech parks. Approval will be sought via postal ballot. Additionally, the 33rd Annual General Meeting (AGM) is scheduled for September 25, 2026.

Board approved name change from 'Shukra Pharmaceuticals Limited' to 'Shukra Medtech Limited'
MOA Clause III(A) amended to add 6 sub-clauses covering medical devices, surgical robotics, AI healthcare, and MedTech parks
Shareholder approval to be sought via postal ballot alongside necessary approvals from MCA/CRC
33rd Annual General Meeting scheduled for September 25, 2026, via Video Conferencing
Register of Members and Share Transfer Books to remain closed from September 19, 2026 to September 25, 2026

💡 Track the upcoming postal ballot voting results, MCA/ROC approval for the name change, and subsequent disclosures on concrete MedTech business investments or partnerships.

Shukra Pharma Clarifies Media Coverage Following NSE Listing on August 14, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 17 Aug 2026, 07:08 PM

Shukra Pharmaceuticals has submitted a clarification under Regulation 30 regarding an ANI media article published on August 14, 2026, concerning its NSE listing and future strategic vision. The company confirmed that its equity shares commenced trading on the National Stock Exchange of India (NSE) on August 14, 2026, making them dual-listed on BSE and NSE. It explicitly clarified that the media reports highlighting Medical Technology and AI represent broad strategic vision and do not involve any new material agreements, orders, or acquisitions.

Equity shares commenced trading on the NSE on August 14, 2026, enabling dual-listing on BSE and NSE.
Clarified an ANI media article published on August 14, 2026 regarding AI and Medical Technology focus.
Confirmed no new material agreements, orders, investments, or acquisitions have been entered into.

💡 Monitor official exchange disclosures for any formal execution milestones or commercial contracts related to medical technology and AI diversification.

Shukra Pharma Board to Meet on Aug 22 to Consider Name Change and Object Clause Revision

🔵 WATCH ⭐ 4/10

BOARD_MEETING 📅 17 Aug 2026, 02:21 PM

Shukra Pharmaceuticals has scheduled a Board of Directors meeting on August 22, 2026, to consider a change in the company name and an alteration to its Object Clause in the Memorandum of Association. The Board will also approve a draft Postal Ballot notice to seek shareholder approval and appoint Mrs. Rupal Patel as scrutinizer. In addition, the agenda includes approving the Director's Report for FY2026 and fixing details for the upcoming Annual General Meeting.

Board meeting scheduled for August 22, 2026, to consider changing company name and Object Clause
Postal ballot notice to be approved alongside appointment of Mrs. Rupal Patel as Scrutinizer
Approval of Director's Report and Secretarial Audit Report for year ended March 31, 2026 on the agenda
Insider trading window closed from August 17, 2026 to August 24, 2026

💡 Monitor the outcome of the August 22, 2026 Board meeting to review the specifics of the proposed object clause alteration and new business directions.

Shukra Pharmaceuticals to Rebrand as Shukra Medtech; Expands into Medical Technology Sector

🔵 WATCH ⭐ 6/10

EXPANSION 📅 14 Aug 2026, 03:29 PM

The Board of Shukra Pharmaceuticals has approved a proposal to change the company's name to 'Shukra Medtech Limited' and expand its business objects to include the Medical Technology (MedTech) sector. This strategic pivot allows the company to engage in R&D, manufacturing, and distribution of medical devices and equipment alongside its existing pharmaceutical business. Financially, the company reported a strong June 2026 quarter with a net profit of Rs 12.96 Cr on revenue of Rs 23.52 Cr. The move is subject to shareholder and regulatory approvals.

Board approved name change to 'Shukra Medtech Limited' on August 14, 2026
Expansion of Main Objects to include MedTech R&D, manufacturing, and distribution
June 2026 quarterly revenue reported at Rs 23.52 Cr with Rs 12.95 Cr net profit
Company maintains a low debt profile of Rs 5 Cr against a net worth of Rs 90 Cr
Promoter holding remains stable at 50.95% as of June 2026

💡 Monitor shareholder approval for the name change and watch for future disclosures regarding specific capital expenditure or product pipelines in the MedTech segment.

37% ROCE Shukra Pharma to Rebrand as Shukra Medtech; Expands into Medical Technology

🔵 WATCH ⭐ 6/10

EXPANSION 📅 14 Aug 2026, 03:18 PM

Shukra Pharmaceuticals' Board has approved a proposal to change the company's name to 'Shukra Medtech Limited' and expand its business objects to include the Medical Technology (MedTech) sector. This strategic shift aims to include R&D, manufacturing, and distribution of medical devices and systems alongside its existing pharmaceutical business. Financially, the company maintains a strong profile with a net worth of Rs 90 Cr and a high ROCE of 37.0%. The expansion is intended to create long-term growth opportunities, pending shareholder and regulatory approvals.

Board approval granted on August 14, 2026, for name change and object expansion.
New business scope covers development, manufacturing, and marketing of MedTech products.
Company reported a quarterly revenue of Rs 23.52 Cr for the period ending June 2026.
Net profit for the same quarter stood at Rs 12.96 Cr, reflecting high operational efficiency.

💡 Monitor shareholder voting results and subsequent announcements regarding specific MedTech product launches or capital expenditure plans for this new segment.

Shukra Pharmaceuticals Lists on NSE Main Board Effective August 14, 2026

🟢 POSITIVE ⭐ 5/10

REGULATORY 📅 14 Aug 2026, 12:02 PM

Shukra Pharmaceuticals has successfully listed its equity shares on the National Stock Exchange (NSE) Main Board, effective August 14, 2026. The company, which was previously only listed on the BSE, will now be dual-listed under the symbol SHUKRAPHAR. The base reference price for the NSE debut was determined by the closing price on the BSE as of August 13, 2026. This move is strategically aimed at enhancing share liquidity and expanding the company's investor base.

Commencement of trading on NSE Main Board effective August 14, 2026
Dual-listing status maintained with existing BSE listing (Scrip Code: 531351)
Base reference price for NSE trading set based on BSE closing price of August 13, 2026
Company reported a Net Worth of Rs 90 Cr and a low Debt of Rs 5 Cr as per latest context

💡 Monitor the shift in trading volumes from BSE to NSE to gauge liquidity improvements. This is a structural capital market update and does not impact the underlying pharmaceutical manufacturing operations.

Shukra Pharmaceuticals Lists on NSE Main Board; Trading Commences August 14, 2026

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 14 Aug 2026, 11:59 AM

Shukra Pharmaceuticals has successfully completed its direct listing on the National Stock Exchange (NSE) Main Board, with trading beginning August 14, 2026. The company will now be dual-listed on both the BSE and NSE, a move intended to enhance stock liquidity and attract institutional investors. This transition follows a strong financial performance in the June 2026 quarter, where the company reported a PAT of ₹12.96 crore on revenue of ₹23.52 crore. The base reference price for NSE trading was set based on the BSE closing price from August 13, 2026.

Commenced trading on the NSE Main Board on August 14, 2026, under the symbol SHUKRAPHAR
Reported a high operating profit of ₹19.14 crore for the quarter ended June 2026
Maintains a strong balance sheet with a low Debt-to-Equity ratio of 0.06 and a Net Worth of ₹90 crore
Promoter holding remains stable at 50.95% as of the June 2026 quarter
The company operates cGMP compliant facilities for tablets, capsules, and liquid injections

💡 Monitor the shift in trading volumes from BSE to NSE to assess liquidity improvements. Investors should also watch for any increase in institutional participation in future shareholding patterns.

₹15.03 Cr Q1 PAT: Shukra Pharmaceuticals Reports 336% YoY Revenue Surge

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 12 Aug 2026, 02:46 PM

Shukra Pharmaceuticals reported a robust Q1 FY27 (ending June 2026) with revenue from operations jumping 336% YoY to ₹23.52 Cr from ₹5.39 Cr. Net profit surged to ₹15.03 Cr, a massive turnaround from the ₹1.73 Cr loss in the preceding March 2026 quarter and a significant increase from ₹1.03 Cr in Q1 FY26. The quarterly profit alone represents approximately 68% of the company's total TTM PAT of ₹22 Cr. While the Pharmaceutical segment drove all revenue, the MedTech segment, effective from October 2025, reported zero revenue for the quarter.

Revenue from operations increased 336% YoY to ₹23.52 Cr from ₹5.39 Cr.
Net profit reached ₹15.03 Cr, representing a 1,360% increase over the ₹1.03 Cr reported in Q1 FY26.
Basic and Diluted EPS rose to ₹0.34 from ₹0.02 in the same quarter last year.
Total expenses were managed at ₹3.82 Cr, resulting in an exceptionally high Profit Before Tax margin of ~84%.
Pharmaceutical segment revenue (including other income) stood at ₹24.06 Cr.

💡 Investors should monitor the sustainability of these high operating margins and watch for the first signs of revenue generation from the newly formed MedTech segment.

₹15.03 Cr PAT: Shukra Pharmaceuticals Reports 336% YoY Revenue Growth in Q1 FY27

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 12 Aug 2026, 02:39 PM

Shukra Pharmaceuticals reported a significant turnaround in Q1 FY27, with revenue from operations surging 336% YoY to ₹23.52 Cr compared to ₹5.39 Cr in the same quarter last year. Net profit reached ₹15.03 Cr, a sharp recovery from the ₹1.73 Cr loss reported in the immediate previous quarter (Q4 FY26). The company's quarterly revenue alone accounts for approximately 41% of its total TTM revenue of ₹57 Cr. While the Pharmaceutical segment drove all revenue, the MedTech segment remains pre-revenue but holds ₹11.55 Cr in assets.

Revenue from operations increased 336% YoY to ₹23.52 Cr from ₹5.39 Cr.
Net profit stood at ₹15.03 Cr, recovering from a loss of ₹1.73 Cr in Q4 FY26.
Earnings Per Share (EPS) improved to ₹0.34 for the quarter from ₹0.02 YoY.
Pharmaceutical segment profit before tax and interest reached ₹20.67 Cr.
MedTech segment assets are recorded at ₹11.55 Cr, indicating future business potential despite zero current revenue.

💡 Investors should monitor the sustainability of these high margins and whether the revenue jump is due to recurring orders or one-off contracts. Watch for any updates regarding the commercialization of the MedTech segment.

Shukra Pharmaceuticals Reschedules Board Meeting to August 12, 2026 for Q1 Results

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 06 Aug 2026, 06:10 PM

Shukra Pharmaceuticals has revised the date of its upcoming Board Meeting from August 11 to August 12, 2026. The primary agenda is to consider and approve the unaudited financial results for the quarter ended June 30, 2026. This follows a challenging March 2026 quarter where the company reported a net loss of ₹1.73 cr despite a TTM revenue of ₹57 cr. Investors should note the high P/E ratio of 67.5 and the significant revenue volatility observed in recent quarters.

Board meeting date revised from August 11, 2026, to August 12, 2026
Agenda includes approval of unaudited financial results for the quarter ended June 30, 2026
Company reported a net loss of ₹1.73 cr in the previous quarter (March 2026)
TTM revenue stands at ₹57 cr with an operating profit margin of 50.7%
Promoter holding remains stable at 50.95% as of June 2026

💡 Monitor the financial results to be released on August 12, 2026, specifically looking for a recovery in profitability after the loss reported in the March 2026 quarter.

Board Meeting Scheduled for August 11, 2026, to Approve Q1 FY27 Results

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 30 Jul 2026, 07:19 PM

Shukra Pharmaceuticals has announced a board meeting on August 11, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. This follows a volatile FY26 where quarterly revenue fluctuated significantly, peaking at ‡39.13 Cr in Dec 2025 before dropping to ‡6.3 Cr in Mar 2026. Investors will be monitoring for a recovery after the company reported a net loss of ‡1.73 Cr in the previous quarter. The company currently maintains a high P/E ratio of 63.2 relative to its TTM revenue of ‡57 Cr.

Board meeting scheduled for August 11, 2026, to approve Q1 FY27 results
Company reported a net loss of ‡1.73 Cr in the most recent quarter (March 2026)
Revenue in the previous quarter (March 2026) was ‡6.3 Cr, down from ‡39.13 Cr in December 2025
TTM revenue stands at ‡57 Cr against a market capitalization of ‡1393 Cr
Promoter holding remains stable at 50.95% as of June 2026

💡 Watch for the earnings release on August 11 to assess if the company can stabilize its revenue and return to the high operating margins (50.7% TTM) seen in previous periods.

₹35.56 Revised Warrant Price: Shukra Pharma Confirms Receipt of Differential Upfront Amount

🟡 NEUTRAL ⭐ 4/10

FUNDRAISE 📅 14 Jul 2026, 07:36 PM

Shukra Pharmaceuticals has confirmed the receipt of ₹18.11 lakhs as differential upfront consideration (25%) for 46,43,000 warrants. This follows a price re-computation from ₹34.00 to ₹35.56 per warrant as per SEBI ICDR regulations. All five promoter-group allottees met the payment deadline of July 13, 2026. Additionally, two allottees paid the remaining 75% differential amount, totaling ₹20.30 lakhs, ensuring full compliance with pricing requirements.

Warrant issue price re-computed from ₹34.00 to ₹35.56 per warrant
Total differential upfront (25%) of ₹18,10,770 received for 46,43,000 warrants
Two allottees paid the balance 75% differential amount totaling ₹20,29,950
All payments completed by the regulatory deadline of July 13, 2026
Warrants were originally allotted on January 28, 2026

💡 Investors should monitor the timeline for the conversion of these 46.43 lakh warrants into equity shares, which will result in equity dilution and provide the company with the remaining 75% of the total issue capital.

View All 524632 Announcements on Live Market Tracking →